Healthtake ApplaA Helsinki-based clinical stage bioformocial company that developed first-class therapeutic APAC for thrombo-category disease has today announced that it has stopped financing a million dollars millions of dollars.
The round of this fund was led by new investors Fahrius Startup and Growth AB (FSG), a Nordic Venture Capital Fund and the European Innovation Council (EIC) Fund. FSG and EIC Fund Jenny and Anti -Wihuri Foundation, Innovter and Gesta Serlachius joined by top finish investors, including the Fine Arts Foundation.
Johanna Esklin will also be a member of the board as a member of the board and FSG partner Alexander Jendel as observer.
PremiseCEO, He said, “We are delighted to secure this fund and bring FSG and EIC funds to the Board of FSG and EIC as the highly experienced VC investor from outside Finland. We are making strong progress, and this financing enables us to complete the three international clinical trials that are running with our APAC and start studying in a phase 2 in PAOD/CLTI. Our innovative methods, vascular injury sites have potential applications throughout the wide range of serious vascular diseases using a heparin protoglycan mymetic with targeting capacity and holding on vascular injury sites. We are looking forward to announcing clinical results from these tests in 2025 and 2026The “
The Applegon is a clinical stage bioformasutical company that develops first-class therapeutic APAC for the treatment of thrombo-inflammatory diseases. The first two leadership hints of the organization are:
- AVF maturity to enable life -saving hemodialysis treatment for patients with kidney disease, preventing maturity failure of AVF,
- To prevent separation between CLTI, CLTI patients and other large cardiovascular events.
Founded on the 21st, the therapeutic APAC was created based on the research on the Hperin Protoglaicans obtained from the Mast Cells edited by Professor Riyata Lassila and associates at the Wihuri Research Institute in Helsinki in Finland, Finland. Applagon FSG Fund, Wihuri Foundation, Innovestor and Serlachius Foundation as well as a syndicate of top Nordic investors with EC funds.
Naturally derived from the Heparin protoglycans obtained from the mast cell, APAC provides chronic antitherombotic and anti-inflammatory action aimed at artery injuries sites At the siteThe
This fund will support the clinical trial start at APAC Phase 2 for threats in Finland for the peripheral arterial artery/chronic organs. APAC is also ready to complete three ongoing clinical trials; Arteriovanus fistula (AVF) is a phase first clinical trial for maturity failure, first episode Pregnancy (Iv) Healthy participants are clinical trials and PAOD patients and healthy participants in 2025 are a pet-impaired clinical trial with Ziraconium-Lelbel APAC.
APAC may be managed by hospital for use and locally or by Iv According to the Invad Applagon – more than 40 participants have yet received APAC without any protection concerns and the initial clinical searches are encouraging.
Johanna askedThe general partner of the FSG, said, “Thrombo-inflammation is a key underlying driver for many cardiovascular diseases. In FSG we look for revolutionary innovations and we have clearly received that with the Applagon’s APAC approach for treatment of this clear unmet medical requirementThe “
[publish_date
